That was a quick turnaround from the announcement late last week about initiating a NASH study. This tells me clearly they are doing so for a BP and things continue to point to GILD. Better mono HIV results in P3, combo pending BLA, GvHD and NASH in P2 should only increase the value to GILD (or other BP) and get CYDY a more significant and better terms on any such licensing deal. Let’s see where this takes us.